2018
DOI: 10.1016/j.bcp.2018.06.006
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: During cellular metabolism, spontaneous oxidative damage to unsaturated lipids generates many electrophilic carbonyl compounds that readily attack cell macromolecules, forming adducts that are potential drivers of tissue dysfunction. Since such damage is heightened in many degenerative conditions, researchers have assessed the efficacy of nucleophilic carbonyl-trapping drugs in animal models of such disorders, anticipating that they will protect tissues by intercepting toxic lipid-derived electrophiles (LDEs) … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
12
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(15 citation statements)
references
References 96 publications
(144 reference statements)
3
12
0
Order By: Relevance
“…It is well-known that during cellular metabolism, spontaneous oxidative damage to unsaturated lipids generates many electrophilic carbonyl compounds which are potential threats to cell survival. Since hydralazine is a well-known carbonyl scavenger (35), we speculated that it can improve SH-SY5Y viability by scavenging Carbonyl moieties.…”
Section: Resultsmentioning
confidence: 99%
“…It is well-known that during cellular metabolism, spontaneous oxidative damage to unsaturated lipids generates many electrophilic carbonyl compounds which are potential threats to cell survival. Since hydralazine is a well-known carbonyl scavenger (35), we speculated that it can improve SH-SY5Y viability by scavenging Carbonyl moieties.…”
Section: Resultsmentioning
confidence: 99%
“…The FDA approved hydralazine in 1953, and because of its effectiveness and safety, it is still prescribed 16 . In addition to its application in the treatment of carbonyl-mediated pathologies, hydralazine was repurposed in the 1980s for the treatment of heart failure and again in the 2000s for cancer epigenetic therapy 17 . More recently we demonstrated that hydralazine activates the NRF2/SKN-1 pathway and extends C. elegans lifespan 18 .…”
Section: Introductionmentioning
confidence: 99%
“…Hydralazine is a reducing reagent that can reduce many oxidizing compounds. 15,16 The current report found that a reaction between hydralazine and the MTS reagent occurred in a time-dependent manner and was completed around 3 h after mixing the two compounds. It was recently reported that the reaction between 100 mM hydralazine and the MTS reagent completed within 2 h. 12 The reaction medium in the Fig.…”
Section: Discussionmentioning
confidence: 63%